Prophylactic indomethacin
|
2.13 (0.99)
|
2.53 (1.13)
|
0.14
|
Treatment of symptomatic PDA
|
2.20 (0.86)
|
2.60 (0.99)
|
0.06
|
Decision of PDA ligation
|
1.87 (0.83)
|
2.40 (0.99)
|
0.02
|
Monitoring during indomethacin administration (e.g., signs and complications)
|
2.60 (0.91)
|
2.73 (0.80)
|
0.41
|
Other PDA treatments (e.g., transfusion, diuretics)
|
2.00 (0.76)
|
2.33 (0.82)
|
0.03
|
PDA treatments in chronic phase
|
1.87 (0.99)
|
2.20 (0.77)
|
0.21
|
Fluid management during PDA treatments
|
2.20 (0.94)
|
2.47 (0.83)
|
0.16
|
Respiratory management during PDA treatments
|
2.13 (0.74)
|
2.47 (0.83)
|
0.06
|
Nutrition during PDA treatments
|
2.27 (0.88)
|
2.47 (0.99)
|
0.32
|
Overall
|
2.14 (0.76)
|
2.47 (0.80)
|
0.02
|
Sheffield Peer Review Assessment Tool
| | | |
Good clinical care
|
4.11 (0.56)
|
4.49 (0.76)
|
0.03
|
Maintain good medical practice
|
3.95 (0.52)
|
4.36 (0.77)
|
0.03
|
Teaching and training
|
4.10 (0.99)
|
4.43 (0.92)
|
0.04
|
Relationship with patients
|
4.67 (0.77)
|
4.89 (0.97)
|
0.08
|
Working relationships with colleagues
|
4.13 (0.36)
|
4.43 (0.73)
|
0.09
|
Overall
|
4.14 (0.42)
|
4.50 (0.71)
|
0.05
|